Telotristat ethyl

Telotristat ethyl (pronunciation: te-lo-TRIS-tat ETH-il) is a medication used in the treatment of carcinoid syndrome not adequately controlled by somatostatin analogue therapy. It is a tryptophan hydroxylase inhibitor, which works by reducing the production of serotonin in the body.

Etymology

The name "Telotristat ethyl" is derived from the Greek words "telos" meaning end, and "tristis" meaning sad, referring to the drug's function of ending the symptoms of carcinoid syndrome. The "ethyl" part of the name refers to the ethyl group present in the chemical structure of the drug.

Pharmacology

Telotristat ethyl is a prodrug that is converted in the body to its active form, telotristat. It works by inhibiting the enzyme tryptophan hydroxylase, which is involved in the production of serotonin. By reducing the levels of serotonin in the body, it helps to alleviate the symptoms of carcinoid syndrome, which are caused by excessive serotonin production.

Clinical Use

Telotristat ethyl is used in the treatment of carcinoid syndrome that is not adequately controlled by somatostatin analogue therapy. Carcinoid syndrome is a condition characterized by flushing, diarrhea, and wheezing, and is caused by certain types of neuroendocrine tumors that produce excessive amounts of serotonin.

Side Effects

Common side effects of telotristat ethyl include nausea, headache, and constipation. Serious side effects may include depression and suicidal thoughts.

Related Terms

• Carcinoid syndrome
• Somatostatin analogue
• Serotonin
• Tryptophan hydroxylase
• Neuroendocrine tumors

External links

• Medical encyclopedia article on Telotristat ethyl
• Wikipedia's article - Telotristat ethyl

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski